Novel Health Strategies team was selected for podium and poster presentations at HTAi 2014 Annual Meeting in Washington, DC on market access strategy, pricing and health economic and outcomes research trends.
These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.
In-person replays of all presentations are available upon request.
Novel's team is presenting a study titled 'Is FDA's Breakthrough Therapy Designation a Game-Changing Trend for Patients and Payers?' at HTAi 2014.
This study analyzed the HEOR, pricing and access trends in breakthrough therapy designations which were granted and approved by the FDA. This study was also recently published in Nature Biotechnology and was featured in news magazines.
Novel's team is presenting the following studies:
'Impact of Essential Health Benefit Benchmark Plans on Patient Choice and Health Outcomes: Analysis of CMS 2014 Plans for Top Five States'
'Is It Possible to Demonstrate Cost Effectiveness of Ultra-Orphan Therapies Within Current Thresholds? Lesson Learned from Published HTAs and Studies'
Date: June 16, 2014